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 Introduction
According to the 2013 National Survey on Drug Use and Health reported by the Substance 
Abuse and Mental Health Services Administration (SAMHSA) 18 million individuals in the 
United States aged 12 or older were reported as needing treatment for an alcohol use 
problem (SAMHSA, 2013). This introduction to a virtual issue for the Alcoholism: Clinical 
and Experimental Research website discusses six recent papers describing new possible 
treatments for alcohol use disorders and their consequences. This virtual introduction is not 
a comprehensive review of the current monumental efforts to find viable treatments for 
alcohol use disorders, but rather a focused review of these recent papers and the issues about 
preclinical drug development that they raise. Gubner et al. (2014) examines whether 
varenicline mediates ethanol conditioned place preference and locomotor sensitization, two 
animal models of aspects of alcohol use disorders. The role of purinergic P2X4 receptors, 
the neuropeptides orexin and melanocortin, and peroxisome proliferator-activated receptors 
(PPARs) in models of ethanol intake are investigated by Franklin et al. (2015), Olney et al. 
(2015), Navarro et al. (2015), and Blednov et al. (2015), respectively. Drew et al. (2015) 
further studies PPARs’ role in neuroinflammation in a model of fetal alcohol spectrum 
disorders (FASD). Together, these papers prompt critical questions concerning how 
preclinical research may lead to better clinical outcomes for those suffering from alcohol use 
disorders.
 Treating Alcohol Use Disorders
Currently, four treatments are approved by the FDA to treat alcohol use disorders; oral and 
intramuscular naltrexone antagonize µ-opioid receptors, acamprosate partially agonizes 
NMDA-mediated glutamatergic signaling, and disulfiram inhibits aldehyde dehydrogenase 
resulting in accumulation of acetaldehyde and subsequent nausea, tachycardia, and other 
unpleasant symptoms. All of these drugs have a treatment goal of abstinence and may 
present with serious side effects that range from nausea and illness to seizures. Nalmefene, 
which works through the opioid receptor system, is also approved in Europe to reduce 
drinking (Connor et al., 2015). However, these drug treatments often exhibit low success 
rates and their effectiveness can be dependent on self-help seeking. Moos and Moos (2006) 
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followed a cohort of individuals after they first sought help for drinking problems. At each 
follow-up they split participants into those who had continued to seek treatment and those 
who had not. At the 3 year follow-up, 43% of the individuals who did not continue to seek 
help and 37.6% of the individuals who continued to seek help were no longer in remission. 
At the 16 year follow-up, 60.5% of the individuals who did not continue to seek help and 
42.9% of the individuals who continued to seek help had relapsed. Although treatment-
seeking was not limited to pharmacological treatment, the results of Moos and Moos (2006) 
indicate that current routes of treatment are not effective for all individuals suffering from 
alcohol use disorders even when they continue seeking help.
Other factors further complicate the pharmacological treatment of alcohol use disorders. 
Only 9% of individuals diagnosed with alcohol dependence actually filled a prescription for 
an FDA approved treatment in 2007 (Mark et al., 2009). Moreover, the rates of receiving 
pharmacotherapy vary greatly from place to place. Thomas et al. (2013) report that only 
15.6% of individuals with private healthcare who had an alcohol dependence encounter 
received pharmacotherapy in 2007. That number dropped to 2.6% of those seeking treatment 
through the Veterans Health Administration (VHA), although the number of individuals 
seeking help through the VHA was more than six times greater than those with private 
insurance. It is important to note that all of the above rates may have increased since 2007 
and do not include medications used off-label to treat alcohol use disorders. Among factors 
that influence low medication rates include poor insurance coverage and high cost, treatment 
philosophies that shun pharmacotherapy, lack of knowledge about pharmacotherapy options 
on the part of both treatment provider and patient, and patient resistance to a diagnosis of 
alcohol use disorder (see Oliva et al., 2011 for review).
Although many drugs are currently in clinical trials to treat alcohol use disorders, it has been 
quite some time since any new treatment has become available. Indeed, the last treatment 
approved by the FDA was extended-release naltrexone in April, 2006 (Pettinati & 
Rabinowitz, 2006). Further, few interventions exist to treat other consequences of alcohol 
use, such as fetal alcohol spectrum disorders (FASD), which are a leading cause of mental 
retardation. FASD is difficult to identify early and may present with a large range of 
symptoms that are similar to other disorders, such as ADHD, but do not respond similarly to 
treatment (Murawski et al., 2015). It is necessary to investigate other non-traditional 
pharmacological treatment options to curb the damage of alcohol use disorders. Because 
clinical trials are long, expensive, and risk harm to humans, preclinical animal models are 
necessary to gather preliminary data on potential treatments and to guide decisions 
concerning when clinical trials are warranted.
 Preclinical Models
The DSM-5 (APA, 2013) places alcohol use disorders on a spectrum of severity. Diagnosis 
is based on self-report of 11 various symptoms such as: “Has drinking recently interfered 
with your every-day responsibilities?” “Do you blindly crave alcohol?” “Have attempts to 
cut down on drinking been unsuccessful?” “Do you feel withdrawal symptoms when you go 
without alcohol?” Researchers are unable to literally ask these questions of preclinical 
animal models, leaving them to find other ways of modeling aspects of, and testing possible 
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treatments for, alcohol use disorders. Egli (2005) outlines the following aspects of alcohol 
use disorders that can be characterized in preclinical models: Consumption, alcohol 
deprivation, reinstatement, conditioned place preference (CPP), and locomotor activity/
sensitization. For potential pharmacological treatments the ideal place to start is ethanol 
consumption. Multiple preclinical models of ethanol exist, such as 24-hour free-choice 
drinking that models chronic intake, binge-like limited-access drinking that may be likened 
to “party” drinking, and operant response paradigms that are able to characterize intake as 
well as motivation to consume ethanol. Although some of these models produce low levels 
of drinking, the oft-employed Drinking-in-the-Dark or chronic intermittent access protocols 
achieve relatively high levels of consumption that correspond to pharmacologically relevant 
alcohol intake (see Crabbe et al., 2011 for review). This is primarily where the selected 
papers start as a means of identifying potential treatments. Surely, a treatment is not viable if 
it is unable to alter the hallmark feature of alcohol use disorders, that being high alcohol 
drinking.
Once a drug has successfully been shown to reduce ethanol intake, often in more than one 
study using more than one model of consumption, it may be tested under the other 
conditions outlined by Egli (2005). A number of other alcohol behaviors beyond intake can 
be modeled. Alcohol deprivation following chronic intermittent ethanol vapor or ethanol 
liquid diet exposure (see Crabbe et al., 2011) results in withdrawal symptomology, and 
treatments may be tested for their efficacy at reducing these withdrawal effects. Extinction, 
wherein ethanol is no longer available following completion of a contingent operant 
response, allows for quantifying craving and motivational drive to receive ethanol. 
Reinstatement of ethanol following extinction in operant paradigms allows researchers to 
investigate whether drugs minimize cues associated with ethanol intake and alcohol seeking. 
The development of a conditioned place preference for ethanol, in which the animal spends 
more time in an area that has been paired with ethanol, is considered a demonstration of 
“liking” the drug. Locomotor stimulation to an acute ethanol injection and sensitization, 
which is increased locomotor response over repeated ethanol injections, may be decreased 
by drugs that reduce ethanol intake. Not mentioned by Egli (2005) is alcohol tolerance, 
which is a critical aspect of alcohol use disorders. Alcohol tolerance can be modeled many 
ways in animals by observing functional and metabolic tolerance, which refer to the 
reduction in behavioral efficacy or the blood ethanol concentration achieved following 
repeated ethanol exposure (see Crabbe et al., 2013 for review).
Gubner et al. (2014) investigated whether varenicline, which successfully reduces ethanol 
intake in humans and preclinical models, also weakens ethanol-induced CPP expression or 
acquisition and expression of locomotor sensitization. Varenicline was unable to block 
expression of CPP or locomotor sensitization, although it did show a trend towards reducing 
sensitization. Acquisition of locomotor sensitization was initially reduced by varenicline but 
recovered over time, indicating no effect of varenicline on locomotor response to ethanol.
While these results are predominately null they still beg important considerations. Is it truly 
necessary for potential treatments to mitigate all aspects of preclinical models? Egli (2005) 
states that alcohol consumption measured in animal models alone is a poorly valid model, 
yet a recent multi-site clinical trial revealed that varenicline reduced number of heavy 
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drinking days, drinks per day, and alcohol craving in individuals meeting alcohol 
dependence criteria (Litten et al., 2013). Egli’s predominant concern is that of false 
positives; many treatments may reduce ethanol intake in animal models without necessarily 
exhibiting clinical effectiveness. This argues for additional preclinical criteria for examining 
drug efficacy. But is it possible that aspects of preclinical models, outside of consumption, 
are currently focusing on the wrong criteria for successful treatments? And how do we 
determine which aspects of the current preclinical models signal clinical success? FDA drug 
approval does not follow a sequential preclinical-to-human laboratory-to-clinical trial order. 
In some cases, such as with dutasteride and baclofen, drugs previously approved for use by 
humans to treat other disorders can be tested in human laboratory or medical office settings 
for off-label use, and preclinical tests occur as supplements to off-label testing (Yardley & 
Ray, 2016). There are also issues in surveying preclinical and human laboratory literature to 
predict clinical trial outcome. These issues include lack of standardization across studies, 
bias towards publishing positive results, and treatment-seeking status of participants (Litten 
et al., 2012a; Yardley & Ray, 2016). One approach to identify predictively valid preclinical 
models may be to test compounds approved by the FDA for alcohol use disorders against 
those that have failed clinical trials and those that are currently in clinical trials across a wide 
array of alcohol-related phenotypes. Results could be compiled in an open-source database 
to circumvent issues with access to publications and publication bias (Litten et al., 2012a).
 Classical Circuitry
The neurobiological systems involved in disorders can be identified via systemic or site-
specific injections of various pharmacological agents. Brain regions of interest vary by their 
classically perceived role in substance abuse behavior. Some of these regions include the 
nucleus accumbens shell and core and ventral striatum for their collective role in 
reinforcement, the dorsal striatum for its role in habit formation, the hippocampus for its role 
in processing drug and alcohol contexts, and the prefrontal cortex for its role in exerting 
executive control over these regions. Considerable research has focused on GABA, 
glutamate, and dopamine receptors as pharmacological targets, as the above brain regions 
are predominately connected by GABAergic, glutamatergic, and dopaminergic projections. 
Focus has also been on compounds that target opioid receptors and, more recently, nicotinic 
acetylcholine receptors due to their prevalence in these regions (see Koob et al., 1998; 
Everitt & Robbins, 2005; Hendrickson et al., 2013 for review of these regions and 
circuitries). Pharmacological manipulation of these targets has been met with moderate 
success. As discussed, naltrexone and nalmefene target the opioid receptor system, whereas 
acamprosate mediates the glutamatergic system (Connor et al., 2015). Drugs targeting 
classical systems currently or recently in clinical trials include the nicotinic receptor partial 
agonist varenicline, the GABAergic drug baclofen, the a2δ voltage-gated calcium channel 
ligand and GABAergic modulator gabapentin, the GABAergic and glutamatergic modulator 
topiramate, and the atypical antipsychotic quetiapine, which acts via dopaminergic, 
serotonergic, and adrenergic mechanisms ((See clinicaltrials.gov for current clinical trial 
information). Of these, all but quetiapine have been shown to be effective in reducing 
ethanol drinking days and number of drinks consumed (Garbutt et al., 2010; Leggio et al., 
2010; Litten et al., 2012b; Litten et al., 2013; Mason et al., 2014; Falk et al., 2015; 
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Guglielmo et al., 2015). However, they often require meetings to monitor compliance, may 
produce significant side effects such as sedation or cognitive impairment, and may be 
dependent on genetic factors for their efficacy (i.e., baclofen’s effects on drinking appear to 
depend on both D4 dopamine receptors and polymorphisms in the serotonin transporter 
gene) (Knapp et al., 2015; Leggio et al., 2013). As researchers make great strides in brain 
discovery, and the classical treatment targets do not hold up to the standards we hope to set, 
the field has started to look for more innovative pharmacological interventions.
 New Horizons
The five remaining papers highlighted in this issue focus on several new horizons in alcohol 
and substance abuse research. The papers discussed herein only scratch the surface of efforts 
to find new, alternative, and exciting treatments for alcohol use disorders. Each of the targets 
discussed are vitally linked to the “classical circuitry” described above and have been shown 
to be effective in some preclinical models of ethanol intake. Franklin et al. (2015) 
investigated the role of purinergic P2X4 receptors across the CNS and specifically in the 
posterior VTA (pVTA), which has long been implicated as an important component of the 
reinforcement circuitry (Rodd-Henricks et al., 2000; Moore & Boehm, 2009). Purinergic 
receptors mediate neuronal activity and the function of many other neurotransmitter systems, 
including those of “classical” interest, and are sensitive to intoxicating levels of ethanol 
(Asatryan et al., 2011). Using selectively bred high alcohol drinking (HAD) rats, Franklin et 
al. (2015) demonstrated that both non-specific agonism using the drug ivermectin and 
pVTA-targeted knockdown of P2X4 receptors reduces ethanol intake. The authors suggested 
that the seemingly contradictory effect of both agonism and knockdown to reduce ethanol 
intake may have been due to ivermectin’s ability to reduce ethanol effects at P2X4 receptors, 
the virus reducing the number of receptors for ethanol to interact with, and ivermectin’s 
effects on non-purinergic systems. Interestingly, HAD-1 males displayed an extended 
reduction of drinking following systemic ivermectin compared to the HAD-2 males, which 
may reflect genetic differences in the selectively bred lines (Franklin et al., 2015; McBride 
et al., 2012).
Work by Olney et al. (2015) and Navarro et al. (2015) sought to further elucidate the role of 
neuropeptides that originate in the hypothalamus in ethanol drinking. Long known to be 
involved in the reinforcement pathway, the hypothalamus gives rise to various 
neurotransmitters and shares connections with many other brain regions, including the 
amygdala, nucleus accumbens, prefrontal cortex, and VTA. It has been implicated in mood 
and anxiety disorders, addiction, and drug effects (Noori et al., 2012). The neuropeptide 
orexin, as well as a group of peptide hormones known as the melanocortins, are involved in 
the various roles of the hypothalamus (Chen et al., 2015; Caruso et al., 2014). Olney et al. 
(2015) pursued two questions; Are there changes in hypothalamic orexin levels following 
binge-like ethanol consumption, and can antagonizing orexin-1 receptors reduce binge-like 
ethanol intake? Both short and extended ethanol and sucrose binge cycles lead to decreased 
orexin-A positive neurons in the lateral hypothalamus, an area specifically associated with 
reinforcement-motivated behavior (Harris et al., 2005). Systemic antagonism of orexin-1 
receptors reduced both ethanol and saccharin intake without affecting locomotion, 
suggesting a non-caloric-specific effect on reinforcers. Navarro et al. (2015) investigated the 
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role of the melanocortin agonist melanotan-II, a synthetic analogue of α-melanocyte-
stimulating hormone that is produced in the arcuate nucleus of the hypothalamus, in ethanol 
drinking. Melanocortin peptides arise from POMC along with beta-endorphins, leading to 
interactions between melanocortin and opioid receptors (Hadley & Haskell-Luevano, 1999). 
Considering the role of opioid receptors in ethanol intake, Navarro et al. (2015) sought to 
establish whether melanotan-II could reduce ethanol intake alone, and whether it could 
produce a synergistic effect with naltrexone, an FDA-approved treatment for alcohol use 
disorders. Using a binge-like intake paradigm, melanotan-II was shown to effectively reduce 
ethanol intake on its own, as well as to significantly shift the potency of naltrexone.
Drew et al. (2015) and Blednov et al. (2015) investigated the role of PPARs in inflammatory 
responses in a model of FASD and two preclinical models of ethanol consumption, 
respectively. PPARs are nuclear receptor proteins that regulate target gene expression. There 
are three distinct isoforms (α, γ, and δ) with diverse patterns of distribution throughout the 
peripheral and central nervous systems, as well as isoform-specific ligands. Fatty acids act as 
their natural ligands and many synthetic ligands have also been identified. PPARs play a key 
role in metabolism and have been researched as treatments for dyslipidemia, diabetes, 
inflammatory disorders, and cancer (Berger & Moller, 2002; Lee & Kim, 2015). PPARs 
became the focus of interest in alcohol research for their involvement in the cannabinoid and 
dopamine systems, and much research has demonstrated their efficacy at reducing ethanol 
intake (see Le Foll et al., 2013 for review). Drew et al. (2015) demonstrated that 
hippocampal, cerebellar, and cortical pro-inflammatory responses are increased and 
dendritic morphology is altered following PND4-9 ethanol administration, and that 
concurrent administration of the PPARγ agonist pioglitazone with ethanol rescued these 
effects. Drew et al. (2015) suggest that, as these brain regions are critical in later deficits 
seen in FASD, future research should focus on whether pioglitazone can be used as a post-
ethanol exposure intervention, and whether the effects of pioglitazone will persist long-term.
PPARs may also be effective treatments to reduce ethanol consumption. Blednov et al. 
(2015) demonstrated both a model- and isoform-specific effect of PPARs. Fenofibrate and 
tesaglitazar, PPARα and PPARα,γ agonists, respectively, reduced chronic and limited 
ethanol intake and preference. The PPARγ and pan agonists were less effective, while the 
PPARδ agonist was completely ineffective. Similar to Blednov et al. (2015), Stopponi et al. 
(2011) demonstrated that the PPARγ-specific agonist pioglitazone reduces 24-hour two-
bottle choice ethanol intake. However, rosiglitazone, which is also a PPARγ-specific agonist, 
does not reduce ethanol intake. Fenofibrate, tesaglitazar, and pioglitazone also significantly 
altered multiple behaviors associated with alcohol consumption. Blednov et al. (2016a) 
demonstrated decreased novelty-induced locomotion, reduced ethanol-induced loss of 
righting reflex, reduced ethanol withdrawal symptoms, and enhanced ethanol metabolism 
with some sex differences. Neither fenofibrate nor tesaglitazar reduced ethanol-induced CPP. 
Fenofibrate and tesaglitazar also altered the genomic profile of GABAergic interneurons in 
the amygdala compared to a PPAR agonist that did not alter ethanol intake (Ferguson et al., 
2014). Pioglitazone reduced operant responses for ethanol, but not saccharin, reduced 
yohimbine-induced (but not cue-induced) ethanol reinstatement, and reduced ethanol 
withdrawal scores independent of PPARα activation (Stopponi et al., 2011). Although the 
ability of PPAR agonists to reduce drinking appears to be dependent on presence of the α 
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subunit, the γ subunit may be critical for enhancing the effects of PPARα agonists on 
alcohol-related behaviors (Stopponi et al., 2011; Blednov et al., 2016a; 2016b).
Non-invasive human research can also be incorporated into preclinical studies. Blednov et 
al. (2015) associated human PPAR single-nucleotide polymorphisms (SNPs) with DMS-IV 
criteria alcohol dependence and withdrawal. Both α and γ were primarily associated with 
withdrawal, whereas the transcriptional coactivator for the PPARG gene, PPARC1A, was 
associated with dependence. PPARD SNPs showed no association. The methodology and 
results of Blednov et al. (2015) highlight some important considerations for preclinical 
research; multiple models should be used, isoform-specific drugs ought to be considered 
when possible, and preclinical researchers may non-invasively link their results to human 
populations.
 Conclusions
Research on alcohol use disorders paints a picture of a varied disease that is difficult to treat. 
Few medical interventions exist, and those that do are not taken advantage of at a high rate 
(Mark et al., 2009). Developing successful treatments requires the use of preclinical animal 
models. However, there is no specific battery of tests that are accepted as sufficient making it 
difficult to determine when a drug has been successful enough in animal models to move it 
forward to clinical testing. The papers highlighted within this virtual issue touch on various 
points of concern and raise questions and directions for the future of the field (see Box 1 for 
summary points). Gubner et al. (2014) demonstrate that varenicline, a drug shown to be 
effective in both preclinical and clinical trials of ethanol consumption, is unable to reduce 
ethanol CPP or locomotor sensitization. But are those constructs directly relevant to the 
human disorder, and should failure of effectiveness in tests outside of ethanol intake stop 
drugs from moving into clinical trials? Further, how much of a concern are non-specific 
effects of drugs? Olney et al. (2015) demonstrated orexin-1 agonism-induced reduction of 
saccharin intake. Considering the entwined nature of food and drug reinforcement pathways, 
such results are not surprising. However, may they be indicative of concerns over general 
effects on motivation and potentially ill-tolerated side-effects in clinical populations? 
Clearly, it is necessary to test for amotivational and anhedonic effects of drugs of interest. 
Navarro et al.’s (2015) results may advise a path when side effects are of concern; 
combining subthreshold doses of two drugs reduced ethanol intake further than either 
effective dose alone. This synergistic effect of subthreshold doses is also seen with 
naltrexone and the PPARγ-specific agonist pioglitazone (Stopponi et al., 2013). Therefore, 
combination of lower drug doses may effectively reduce ethanol intake without ill-tolerated 
side effects. Also of consideration is repeated dosing, which is not always used in preclinical 
testing. Blednov et al. (2015) and Franklin et al., (2015) employed repeated dosing 
procedures and found effects of lower drug doses that were not evident on the first day of 
drug administration. Considering that approved medications are designed for use over a 
repeated course, employing repeated testing of a drug dose-range may be useful.
Another question concerns how we effectively consider genetics in potential drug efficacy? 
Multiple studies have shown clear genetic associations with drug effectiveness in clinical 
populations (e.g. Leggio et al., 2013; Kranzler et al., 2011; 2014), which can be reflected in 
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preclinical populations, such as the differences in P2X4 expression and agonist efficacy in 
HAD-1 versus HAD-2 rats (Franklin et al., 2015). Genetic association studies may also 
indicate success of drugs with certain receptor selectivity. Blednov et al. (2015) found that 
PPARα and γ, but not δ, agonists effectively reduced ethanol intake in two different models. 
In the COGA analysis, the PPARA and PPARG genes, but not PPARD gene, were associated 
with alcohol withdrawal, indicating that non-invasive human studies may be able to guide 
preclinical testing targets. These findings support the drive for personalized medicine based 
on genetic predisposition for alcohol use disorders, comorbid disorders, features of the 
alcohol use disorder, and other criteria that may be of concern. One major advantage of 
preclinical models is the ability to manipulate genetic predisposition toward high alcohol 
intake and other associated phenotypes. Animal lines identified as having high or low 
ethanol consumption, such as P rats or the High Alcohol Preferring (HAP) mice, may be 
analyzed for unique genes that contribute to intake (Mulligan et al., 2006). Genetic targets 
may also be pulled from open source databases, such as the Integrative Neuroscience 
Initiative on Alcoholism (INIA) Texas Gene Expression Database (http://
inia.icmb.utexas.edu/). These genes can then be conditionally or permanently altered via 
methods such as receptor knockout or designer receptors exclusively activated by designer 
drugs (DREADDs) (see Roth, 2016) to further understand the relationship between alcohol 
consumption, alcohol-related phenotypes, and specialized treatment in animal models of 
alcohol use and comorbid disorders.
Alcohol use disorders pose a major threat to individuals and society. They result in loss of 
friends and family, increased rates of illness, loss of life of the individual or bystanders, and 
individual economic instability as well as increased economic costs to support those 
suffering. The current rates of those seeking medical treatment are low, existing treatment 
outcomes are bleak, and current pharmacological treatments come with contraindications 
and warnings that may exacerbate existing health issues (SAMHSA, 2015). New drug 
interventions cannot be identified fast enough. Fortunately the preclinical field is rapidly 
advancing new targets to treat alcohol use disorders. Rigorous criteria will need to be 
identified for when a drug is ready to move into clinical trials. These considerations include 
examining behavior across an expanse of testing paradigms, whether a failure under certain 
behavioral testing paradigms excludes a drug from moving forward, side effect profiles, 
repeated-dosing and using low or combined drug doses, and genetic contribution to efficacy.
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Box 1
Key Considerations
❖ How should the preclinical research community determine which preclinical models may signal 
treatments that would successfully make it through clinical trials?
❖ Should failure of treatment effectiveness in preclinical behavioral tests related to ethanol 
consumption stop a drug from moving to preclinical trials?
❖ Considering the similar underlying pathways of food, drug, and other natural reinforcements, when 
do non-specific drug effects become a red flag?
❖ How do we effectively consider aspects of personalized medicine, such as genetic contributions?
Suggestions
❖ Test drugs that have and have not passed FDA clinical trials for alcohol use disorders in a large 
range of behavioral tests in an attempt to find critical aspects that may suggest success.
❖ Maintain open source preclinical, human laboratory, and clinical trial databases with positive and 
negative results that can easily be cross-referenced.
❖ Consider combined subthreshold doses of efficacious drugs that display anhedonic or amotivational 
effects.
❖ Cross-reference human findings to identify genetic targets which can be manipulated in preclinical 
models.
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